Skip to main content

Share story

Robotics

Robo.ai subsidiary secures first commercial order for 30,000 hours of embodied AI robot training data

Robo.ai subsidiary secures first commercial order for 30,000 hours of embodied AI robot training data Image: Primary
DUBAI, UAE, Feb. 12, 2026 - Robo.ai Inc. said its subsidiary has secured its first commercial order for Embodied AI robot training data. Under the agreement, the subsidiary will provide 30,000 hours of data to U.S.-based DaBoss.AI Inc. over a 12-month delivery period. The scope includes high-value multi-modal raw data such as RGB-D vision, 6-DoF motion trajectories, and force/tactile feedback. The data is designed for training Level 4 and above Embodied AI models. Revenue from the transaction will be consolidated into Robo.ai's financial statements through the holding joint venture under U.S. GAAP. This contract marks the substantive launch of the Embodied AI Data Port strategy. Aiden Zhu, co-founder and U.S. CEO of DaBoss, said the order marks the successful transition of data acquisition from heavy-asset operations to an elastic cloud service model. Benjamin Zhai, CEO of Robo.ai, said the order demonstrates urgent global market demand for high-quality physical common sense data.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from PR Newswire and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.